Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

By C. Hézode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J. Bronowicki, M. Bourlière, S. Gharakhanian, L. Bengtsson and 8 more. New England Journal of Medicine, 2009

1,093 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e9998d86631f69d5570290c56abe7fe3b4fa53ce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Holtzman
2. J. Ward
3. R. Morgan
4. Bryce D. Smith
5. Y. Falck-Ytter
6. C. Teo
7. Amy Jewett
8. N. Patel

Citations in the corpus

• EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy (2011, neutral): “Although newly developed antiviral substances targeting HCV protein processing have been shown to improve virological response, toxicity and resistance remain major challenge”
• Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. (2012, positive): “HCV care and treatment recommendations have been issued by AASLD and endorsed by the Infectious Disease Society of America (IDSA) and the American Gastroenterological Association (AGA) (18).”
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection (2011, neutral): “New England Journal of Medicine, Massachusetts Medical Society, 2011, 364 (13), pp.”
• Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection (2011, neutral): “Rash events of any severity† 40 (7) 14 (9) 10 (6) 9 (8) 7 (7)”